Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 1.00 |
| ▸ | TNKS | O95271 | 1/20 | 1.00 |
| ▸ | PARP15 | Q460N3 | 1/20 | 1.00 |
| ▸ | PARP14 | Q460N5 | 1/20 | 1.00 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 1.00 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 1.00 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 1.00 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 1.00 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 1.00 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.95 |
| ▸ | BRD4 | O60885 | 3/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.56 |
| ▸ | TERT | O14746 | 1/20 | 0.54 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pj34 SCHEMBL29355630 | 1.00 | PARP1 (1.00) | PARP1TNKSPARP15PARP14PARP10 | |
| Pj34 SCHEMBL29375455 | 1.00 | PARP1 (1.00) | PARP1TNKSPARP15PARP14PARP10 | |
| Pj34 SCHEMBL29478302 | 0.99 | PARP1 (0.98) | PARP1TNKSPARP15PARP14PARP10 | |
| Pj34 SCHEMBL29419962 | 0.99 | PARP1 (0.98) | PARP1TNKSPARP15PARP14PARP10 | |
| Pj34 SCHEMBL5074001 | 0.99 | PARP1 (0.98) | PARP1TNKSPARP15PARP14PARP10 | |
| Pj34 SCHEMBL31153313 | 0.98 | TRPM2 (1.00) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL20286631 | 0.89 | PARP1 (0.80) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL4728869 | 0.88 | PARP1 (0.79) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL22023552 | 0.88 | PARP1 (0.79) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL6691492 | 0.86 | PARP1 (0.75) | PARP1TNKSPARP15PARP14PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889707-B2 | Treatment of addiction | COHEN-ARMON, Malka (IL) | 2014-11-18 | — | — | US | claimed |
| US-20130203801-A1 | TREATMENT OF ADDICTION | COHEN-ARMON, Malka (IL) | 2013-08-08 | — | — | US | claimed |
| US-20120022026-A1 | METHOD OF TREATING CANCER | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2012-01-26 | — | — | US | claimed |
| EP-2387403-A1 | METHOD OF TREATING CANCER | Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) | 2011-11-23 | — | — | EP | claimed |
| US-20110253692-A1 | Electrical heater for vehicle windshields and windows | SCHAUBLE RICHARD EGON | 2011-10-20 | — | — | US | claimed |
| EP-1684736-B1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARM LTD (GB) | 2011-08-24 | — | — | EP | claimed |
| WO-2010082821-A1 | METHOD OF TREATING CANCER | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2010-07-22 | — | — | WO | claimed |
| US-20260110035-A1 | DNA REPAIR SIGNATURE AND PREDICTION OF RESPONSE FOLLOWING CANCER THERAPY | AGENDIA N V (NL) | 2026-04-23 | — | — | US | disclosed |
| US-20260049359-A1 | PREDICTION OF RESPONSE TO IMMUNE THERAPY IN BREAST CANCER PATIENTS | AGENDIA, INC. | 2026-02-19 | — | — | US | disclosed |
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240240155-A1 | Organoid-Derived Monolayers and Uses Thereof | HUB ORGANOIDS IP B.V. (NL) | 2024-07-18 | — | — | US | disclosed |
| US-20240240155-A1 | Organoid-Derived Monolayers and Uses Thereof | HUB ORGANOIDS IP B.V. (NL) | 2024-07-18 | — | — | US | disclosed |
| EP-1684736-A1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | Kudos Pharmaceuticals Limited (GB) | 2006-08-02 | — | — | EP | disclosed |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | KUDOS PHARMACEUTICALS LIMITED | 2005-10-13 | — | — | US | disclosed |
| WO-2005053662-A1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
| US-6723733-B2 | POLYMERASE INHIBITOR | GUILFORD PHARMACEUTICALS, INC. | 2004-04-20 | — | — | US | disclosed |
| US-20020006927-A1 | Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses | EISAI INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001090077-A1 | SULFONAMIDE AND CARBAMIDE DERIVATIVES OF 6(5H)PHENANTHRIDINONES AND THEIR USES | GUILFORD PHARMACEUTICALS, INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | PARP1, PARP2, PARP3 | PARP1 1/4885TNKS 15/4885PARP15 9/4885 |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | PARP1, PARP2, PARP11 | PARP1 1/4885TNKS 14/4885PARP15 13/4885 |
| US-20260110035-A1 | DNA REPAIR SIGNATURE AND PREDICTION OF RESPONSE FOLLOWING CANCER THERAPY | BRCA1, PARP3, PARP2 | PARP1 4/4885TNKS 60/4885PARP15 17/4885 |
| US-20020006927-A1 | Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses | PARP1, PARP2, PARP6 | PARP1 1/4885TNKS 25/4885PARP15 4/4885 |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | MRE11, PARP2, ERCC4 | PARP1 4/4885TNKS 80/4885PARP15 37/4885 |
| US-20260049359-A1 | PREDICTION OF RESPONSE TO IMMUNE THERAPY IN BREAST CANCER PATIENTS | BRCA1, PDCD1, CD274 | PARP1 1484/4885TNKS 2050/4885PARP15 2654/4885 |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | MRE11, ERCC4, PARP2 | PARP1 7/4885TNKS 82/4885PARP15 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.